2013年

Chronic inflammatory demyelinating polyneuropathy associated with primary biliary cirrhosis.
Murata KY, Ishiguchi H, Ando R, Miwa H, Kondo T.
J Clin Neurosci. 2013 Dec;20(12):1799-801
New and future treatments for neurological disorders--knowledge essential to daily clinics and future prospects. Topics: 4. Parkinson's disease: progress in the medical treatment.
Izawa M, Ito H.
Nihon Naika Gakkai Zasshi. 2013 Aug 10;102(8):1938-45.
Optineurin suppression causes neuronal cell death via NF-κB pathway.
Akizuki M, Yamashita H, Uemura K, Maruyama H, Kawakami H, Ito H, Takahashi R.
J Neurochem. 2013 Sep;126(6):699-704. doi: 10.1111/jnc.12326. Epub 2013 Jun 17.
PMID:23721573
Levodopa challenge test and (123) I-metaiodobenzylguanidine scintigraphy for diagnosing Parkinson's disease.
Asayama S, Wate R, Kaneko S, Asayama T, Oki M, Tsuge A, Nagashima M, Morita J, Nakamura S,Nakamura M, Nishii M, Fujita K, Saito A, Nakano S, Ito H, Kusaka H.
Acta Neurol Scand. 2013 Sep;128(3):160-5. doi: 10.1111/ane.12104. Epub 2013 Feb 15.
PINK1 and Parkin complementarily protect dopaminergic neurons in vertebrates.
Matsui H, Gavinio R, Asano T, Uemura N, Ito H, Taniguchi Y, Kobayashi Y, Maki T, Shen J, Takeda S, Uemura K, Yamakado H, Takahashi R.
Hum Mol Genet. 2013 Jun 15;22(12):2423-34. doi: 10.1093/hmg/ddt095. Epub 2013 Feb 27.
Response to comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells".
Egawa N, Kitaoka S, Tsukita K, Naitoh M, Takahashi K, Yamamoto T, Adachi F, Kondo T, Okita K, Asaka I, Aoi T, Watanabe A, Yamada Y, Morizane A, Takahashi J, Ayaki T, Ito H, Yoshikawa K, Yamawaki S, Suzuki S, Watanabe D, Hioki H, Kaneko T, Makioka K, Okamoto K, Takuma H, Tamaoka A, Hasegawa K, Nonaka T, Hasegawa M, Kawata A, Yoshida M, Nakahata T, Takahashi R, Marchetto MC, Gage FH, Yamanaka S, Inoue H.
Sci Transl Med. 2013 Jun 5;5(188):188lr2. doi: 10.1126/scitranslmed.3005697.
Aberrant assembly of RNA recognition motif 1 links to pathogenic conversion of TAR DNA-binding protein of 43 kDa (TDP-43)
Shodai A, Morimura T, Ido A, Uchida T, Ayaki T, Takahashi R, Kitazawa S, Suzuki S, Shirouzu M, Kigawa T, Muto Y, Yokoyama S, Takahashi R, Kitahara R, Ito H, Fujiwara N, Urushitani M.
J Biol Chem. 2013 May 24;288(21):14886-905. doi: 10.1074/jbc.M113.451849. Epub 2013 Apr 4.
ATP13A2 deficiency induces a decrease in cathepsin D activity, fingerprint-like inclusion body formation, and selective degeneration of dopaminergic neurons.
Matsui H, Sato F, Sato S, Koike M, Taruno Y, Saiki S, Funayama M, Ito H, Taniguchi Y, Uemura N, Toyoda A, Sakaki Y, Takeda S, Uchiyama Y, Hattori N, Takahashi R.
FEBS Lett. 2013 May 2;587(9):1316-25. doi: 10.1016/j.febslet.2013年02月04日6. Epub 2013 Mar 13.
Activation of transforming growth factor-β/Smad signaling reduces aggregate formation of mislocalized TAR DNA-binding protein-43.
Nakamura M, Kaneko S, Ito H, Jiang S, Fujita K, Wate R, Nakano S, Fujisawa JI, Kusaka H. Neurodegener Dis. 2013;11(4):182-93. doi: 10.1159/000338151. Epub 2012 Jul 10.
Regionally different immunoreactivity for Smurf2 and pSmad2/3 in TDP-43-positive inclusions of amyotrophic lateral sclerosis.
Nakamura M, Kaneko S, Wate R, Asayama S, Nakamura Y, Fujita K, Ito H, Kusaka H.
Balloon dilation in sporadic inclusion body myositis patients with Dysphagia.
Murata KY, Kouda K, Tajima F, Kondo T.
Clin Med Insights Case Rep. 2013;6:1-7. doi: 10.4137/CCRep.S10200. Epub 2013 Jan 14.
Myelin-associated glycoprotein-related neuropathy associated with psoriasis: a case report.
Murata KY, Miwa H, Kondo T.
J Med Case Rep. 2013 Jan 3;7(1):4. doi: 10.1186/1752-1947年7月4日.

PAGE TOP

AltStyle によって変換されたページ (->オリジナル) /